HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on CalciMedica (NASDAQ:CALC) and maintains a $20 price target.
April 01, 2024 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on CalciMedica and maintains a $20 price target.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst like Joseph Pantginis could positively influence investor sentiment towards CalciMedica. This endorsement suggests a strong belief in the company's future performance and potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100